Clinical Trials Browser

Active not recruiting × Has results × Melanoma × Clear all

NCT02506153 2026-04-13

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT02656706 2026-04-13

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Phase 2 Active not recruiting

22 enrolled 10 charts

Melanoma

NCT04099251 2026-04-09

CheckMate76K

Phase 3 Active not recruiting

790 enrolled 18 charts 2 FDA

Melanoma

NCT06101134 2026-04-09

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Phase 2 Active not recruiting

100 enrolled 11 charts

Melanoma, Neoplasm Metastasis, Patient Preference

NCT06099782 2026-04-08

MK-3475A-F11

Phase 2 Active not recruiting

147 enrolled 14 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT00937937 2026-03-20

Dinaciclib in Treating Patients With Stage IV Melanoma

Phase 2 Active not recruiting

72 enrolled 14 charts

Melanoma

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Active not recruiting

71 enrolled 9 charts

Melanoma

NCT02362594 2026-03-05

MK-3475-054

Phase 3 Active not recruiting

1,019 enrolled 16 charts 2 FDA

Melanoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Phase 2 Active not recruiting

14 enrolled 9 charts

Melanoma

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Phase 3 Active not recruiting

1,150 enrolled 6 charts

Melanoma

NCT01274338 2026-02-18

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,673 enrolled 19 charts

Melanoma

NCT02224781 2026-02-18

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Phase 3 Active not recruiting

267 enrolled 8 charts

Melanoma

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Phase 1 Active not recruiting

11 enrolled 11 charts

Melanoma

NCT00539591 2025-12-23

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Phase 2 Active not recruiting

29 enrolled 28 charts

Melanoma

NCT03149029 2025-12-05

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

Phase 2 Active not recruiting

16 enrolled 10 charts

Melanoma

NCT04284774 2025-12-04

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Phase 2 Active not recruiting

5 enrolled 9 charts

CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Wilms Tumor, Neuroblastoma, Pheochromocytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Thyroid Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT01708941 2025-11-26

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

88 enrolled 14 charts

Melanoma

NCT01134614 2025-11-25

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Active not recruiting

245 enrolled 8 charts

Melanoma

NCT02965716 2025-11-18

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Phase 2 Active not recruiting

43 enrolled 18 charts

Melanoma

NCT03816332 2025-10-09

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Phase 1 Active not recruiting

12 enrolled 13 charts

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 2 FDA

Melanoma, Neoplasms

NCT02581930 2025-09-08

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Phase 2 Active not recruiting

18 enrolled 10 charts

Melanoma

NCT05061134 2025-07-31

MONETTE

Phase 2 Active not recruiting

194 enrolled 21 charts

Melanoma

NCT05308901 2025-07-25

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Phase 2 Active not recruiting

6 enrolled 11 charts

Uveal Melanoma, Melanoma

NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Phase 1/2 Active not recruiting

15 enrolled 12 charts

DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT02743819 2025-06-10

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Phase 2 Active not recruiting

70 enrolled 11 charts

Melanoma

NCT03719131 2025-04-22

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Phase 2 Active not recruiting

15 enrolled 10 charts

Melanoma

NCT01416831 2025-03-17

SBRT/IL-2

Phase 2 Active not recruiting

44 enrolled 12 charts

Melanoma

NCT03553836 2024-11-29

KEYNOTE-716

Phase 3 Active not recruiting

976 enrolled 15 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma